Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

On November 19, 2026 Adcendo ApS ("Adcendo"), a biotech company focused on the development of differentiated antibody-drug conjugates (ADCs) for cancers with high unmet medical need, reported initial data from the ongoing Phase 1 ADCElerate1 trial evaluating ADCE-D01, a first-in-class ADC against the novel target uPARAP, in patients with advanced soft tissue sarcoma (STS). The data were highlighted in a late-breaking oral presentation during the plenary session on clinical trials at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), taking place November 18-20 in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Dr. Patrick Schöffski, MPH, Head of the Department of General Medical Oncology at the University Hospitals Leuven, Professor in the Department of Oncology at KU Leuven, Belgium, and principal investigator of the ADCElerate1 trial, commented: "Advanced soft tissue sarcoma remains one of our most challenging clinical areas, where historic second-line options routinely yield response rates of only 4 – 10%. The observed 30% objective response rate and high disease control rate seen with ADCE-D01 could mark an important shift, offering a desperately needed novel therapy across STS subtypes for patients who have exhausted standard therapies."

Dr. Lone H. Ottesen MD, PhD, Chief Medical Officer of Adcendo, said: "We are extremely pleased to share the first clinical data for ADCE-D01 at ENA which demonstrate encouraging antitumor activity and disease control across multiple STS subtypes in a population with substantial unmet medical need. We believe these data point to ADCE-D01’s transformative treatment potential, while also validating Adcendo’s target biology and indication-driven approach to developing a pipeline of highly effective and well tolerated ADCs. Together with world leading sarcoma centers in the US and Europe, we continue to enroll patients in the ADCElerate1 study as we work to further explore ADCE-D01’s potential and define the development path."

ADCE-D01 Demonstrates Compelling Antitumor Activity Across Multiple STS Subtypes

Among the 27 response-evaluable patients representing 12 different STS subtypes who received ADCE-D01 every 2 weeks (Q2W), 8 patients had a partial response (PR) for an objective response rate of 30% (5 confirmed, 3 currently unconfirmed), and the disease control rate was 85% (23/27). A trend towards improved efficacy at higher dose levels was observed. Median follow-up was 3.4 months, and the median duration of response had not yet been reached. At data cutoff, all responses were ongoing and 81% (22/27) of evaluable patients remained on treatment.

ADCE-D01 Demonstrates Manageable Safety and Tolerability

47 adults with advanced STS including 17 different subtypes, who had received prior systemic treatment including chemotherapy and targeted agents (a median of two prior lines of therapy [range 1-4]) were enrolled into the study. The first 18 patients received ADCE-D01 on a weekly dosing schedule at a dose of 0.5–3.4 mg/kg. After establishing that dosing Q2W was more suitable due to the pharmacokinetics observed on the weekly dosing schedule, the next 29 patients were dosed at 3.4-5.5 mg/kg Q2W. All patients receiving more than 3.4 mg/kg were also given prophylactic treatment with granulocyte colony-stimulating factor (G-CSF).

The most common treatment-related side effects on the Q2W schedule were low-grade nausea (59%), infusion related reactions (41%), tiredness (38%), and hair loss (35%). The most common hematological side effect was neutropenia (31%). On the Q2W schedule, side effects led to a dose reduction in 10% of patients, and no patients needed to discontinue treatment for side effects. With prophylactic G-CSF, severe (grade 3 or higher) neutropenia occurred in 14% (3/22) of patients, compared with 43% (3/7) of patients without prophylactic G-CSF, even though the patients given G-CSF were receiving higher doses. The maximum tolerated dose (MTD) for the Q2W regimen has not yet been reached. No cases of interstitial lung disease, febrile neutropenia or stomatitis were observed.

Recruitment on the Q2W schedule is ongoing. ADCE-D01 has received Fast Track and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of STS.

Oral Presentation Details:

Title: A novel antibody-drug conjugate targeting urokinase plasminogen activator receptor-associated protein in previously treated patients with advanced soft tissue sarcoma: emerging clinical results from the phase 1 ADCElerate1 study (NCT06797999)
Presenter: Dr. Patrick Schöffski, University Hospitals Leuven and KU Leuven, Belgium
Session: Plenary Session 3 – Proffered Papers: Clinical Trials
Abstract number: 4LBA (ENA26-0411)
Date and time: Thursday, November 19, 2026, at 10:00 a.m. CET / 4:00 a.m. ET

Following the conclusion of the presentation at the meeting, a copy of the oral presentation will be available on the Key Publications page of the Company’s website at www.adcendo.com.

About the ADCElerate1 Trial

ADCElerate1 (NCT06797999) is a first-in-human Phase I/II multicenter, open-label, dose escalation and expansion study evaluating ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS. The primary objective of the study is to evaluate the safety and tolerability of ADCE-D01. The secondary objectives are to characterize the pharmacokinetic profile and to evaluate the preliminary efficacy of ADCE-D01. The study is recruiting in the US and Europe.

About ADCE-D01

ADCE-D01 is a novel ADC targeting uPARAP, an endocytic receptor overexpressed in a wide spectrum of cancers of mesenchymal origin, including soft tissue sarcoma (STS), osteosarcoma, GIST, mesothelioma, and glioblastoma.

uPARAP is an attractive ADC target due to its rapid internalization driven by constitutive target recycling, as well as its highly differentiated expression profile between tumor and healthy tissues. ADCE-D01 combines a novel uPARAP binding antibody designed to avoid interference with the natural receptor ligand, collagen, with a clinically validated protease-cleavable linker and potent deruxtecan payload. Preclinical studies have demonstrated strong anti-tumor activity across a range of in vivo models, as well as a highly encouraging toxicology profile, positioning ADCE-D01 as a promising treatment candidate for patients with STS and other cancers of mesenchymal origin, with the potential to deliver meaningful clinical benefit.

ADCE-D01 received Fast Track Designation and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue sarcoma.

About Soft Tissue Sarcoma

Soft tissue sarcomas are rare and highly heterogeneous cancers comprising more than 100 different tumor subtypes, with an estimated incidence of 4-5 cases per 100,000 people annually in Europe and ~3.5 new diagnoses per 100,000 people in the United States each year.

(Press release, ADCendo, NOV 19, 2026, View Source;antitumor-activity-with-adce-d01-in-advanced-soft-tissue-sarcoma-in-late-breaking-oral-presentation-at-2026-eortc-nci-aacr-symposium-on-molecular-targets-and–302942421.html [SID1234675009])

Velzatinib granted Orphan Drug Designation (ODD) in Japan in GIST

On November 19, 2026 GSK plc (LSE/NYSE: GSK) reported that velzatinib, a novel, highly selective KIT inhibitor, has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST). The ODD was supported by data from the ongoing phase I/Ib StrateGIST 1 trial in advanced GIST, which showed promising anti-tumour activity and a promising tolerability profile.1 In addition to the ODD in Japan, velzatinib has been granted US Food and Drug Administration (FDA) Fast Track designation, and US and European Union (EU) ODD.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GSK is accelerating the development of velzatinib, with phase III trials under way in first- and second-line advanced / metastatic GIST. 2,3 Enrolment in the second-line clinical trial is tracking ahead of schedule, reflecting strong interest in velzatinib from the GIST community, with data expected in the second half of 2027.

Additional data for velzatinib will be shared at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2026 (18-21 November, Seoul, South Korea). Seven abstracts will be presented, including clinical analyses of velzatinib in first- and second-line GIST by KIT mutation, preclinical research on mutation coverage and work on translational biomarkers. These data will further support velzatinib’s development across different KIT mutations and lines of therapy, where resistance and tolerability remain significant challenges.

About velzatinib
Velzatinib is a novel, highly selective KIT inhibitor specifically designed for gastrointestinal stromal tumour (GIST). This monotherapy targets all clinically relevant primary and key secondary KIT mutations, addressing a major unmet need in GIST treatment where tolerability is challenging and resistance arises from diverse KIT mutations.

About GIST
Gastrointestinal stromal tumour (GIST) is a rare type of cancer most commonly arising in the stomach and small intestine. Globally, approximately 80,000 to 120,000 patients are diagnosed with GIST annually.4 80% of GIST cases are driven by mutations in the KIT gene that lead to the growth, proliferation and survival of tumour cells (primary or activating mutations in exons 9 and 11).5 Additionally, about 90% of patients treated in the 1st-line develop new KIT mutations (secondary or resistance mutations in exons 13 and 17) that typically lead to relapse with limited therapeutic options.6 There are no approved tyrosine kinase inhibitors (TKIs) that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT.

In Japan, the age-adjusted annual incidence of GIST is one of the highest in the world, at approximately 4 per 100,000 people.7 While outcomes for people with GIST have improved over the past two decades, the five-year survival rate remains significantly lower once the disease has spread.8 An additional phase II trial with velzatinib – StrateGIST J – is underway in Japan, evaluating patients whose disease has progressed, or who are intolerant to available treatment options.

(Press release, GlaxoSmithKline, NOV 19, 2026, View Source [SID1234674993])

Registrational Phase III AMPLIFY trial: Follow-up assessments completed for all participants

On November 19, 2026 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, reported that the last patient has completed their final follow-up assessments in the Phase III diagnostic 64Cu-SAR-bisPSMA trial, AMPLIFY (NCT06970847)[1].

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AMPLIFY (64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer) is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of 64Cu-SAR-bisPSMA positron emission tomography (PET) in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment at clinical sites across the US and Australia.

The aim of this registrational study is to investigate the diagnostic ability of 64Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer in men with PSA levels above 0.2 ng/mL. The study co-primary endpoints are participant-level correct detection rate (CDR) and region-level positive predictive value (PPV) assessed independently for same-day and next-day imaging (1-4 hours and approximately 24 hours post-administration, respectively). The AMPLIFY study also has a number of exploratory endpoints, such as direct comparisons of 64Cu-SAR-bisPSMA to standard-of-care (SOC) prostate-specific membrane antigen (PSMA) PET agents.

AMPLIFY commenced in May 2025, seeking to enrol approximately 220 participants, and the first trial participant was imaged in the same month at XCancer with Dr Luke Nordquist (Omaha, NE). The target number of participants in the AMPLIFY study was achieved in March 2026, with the rapid pace of recruitment underscoring the substantial unmet need for improved diagnostic imaging in the biochemical recurrence (BCR) setting.

Most recently, Clarity was granted Breakthrough Therapy designation for 64Cu-SAR-bisPSMA in BCR of prostate cancer by the United States (US) Food and Drug Administration (FDA)[2]. Breakthrough Therapy designation is a process designed to expedite the development and review of products that are intended to treat a serious condition, and preliminary clinical evidence indicates that the agent may demonstrate substantial improvement over available products on a clinically significant endpoint(s)[3]. The Breakthrough Therapy designation was supported by the Phase I/IIa COBRA[4] and Phase II Co-PSMA[5] trials as well as real-world evidence[6]. This evidence has collectively demonstrated enhanced imaging capabilities of 64Cu-SAR-bisPSMA over SOC PSMA PET in patients with BCR of prostate cancer[4]-[6].

The Breakthrough Therapy designation represents the latest in a series of US FDA recognitions for the SAR-bisPSMA platform. Prior to receiving Breakthrough Therapy designation, 64Cu-SAR-bisPSMA had already received two Fast Track designations spanning PET imaging in patients with suspected metastasis who are candidates for initial definitive therapy[7] and those with BCR following definitive therapy[8], with the latter supported primarily by data from the COBRA study[4]. This regulatory recognition extends across the broader SAR-bisPSMA program, with 67Cu-SAR-bisPSMA also receiving Fast Track designation for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) following androgen receptor pathway inhibitor [ARPI] and androgen deprivation therapy [ADT])[9].

64Cu-SAR-bisPSMA is also currently being evaluated in another registrational Phase III trial, CLARIFY (NCT06056830)[10], which is expected to complete last participant assessments in calendar year (CY) 2026. Building on the Phase I PROPELLER[11] study, the objective of CLARIFY is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET across same-day and next-day imaging in detecting prostate cancer within the pelvic lymph nodes in patients who are scheduled to undergo radical prostatectomy and pelvic lymph node dissection.

Topline data from the AMPLIFY and CLARIFY trials are anticipated to be released in the first half of CY2027. As pivotal trials, the final study results are intended to provide sufficient evidence to support applications to the US FDA for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in BCR (AMPLIFY) and in prostate cancer patients prior to undergoing definitive therapy (CLARIFY).

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, "The completion of all patients’ follow-ups is an important step as our team and collaborators continue to work with all participating sites on the entry of the final data. This will be followed by analysis and release of topline results, expected in the first half of CY2027. We look forward to commencing our module submissions for our New Drug Application (NDA) with the US FDA under their rolling review process as part of the Breakthrough Therapy designation.

"What we find extraordinary about our SAR-bisPSMA BCR program is that, to our knowledge, this is the first time in the history of the US FDA Breakthrough Therapy designation program that an Australian company (Clarity) has received the designation for a product that was invented and developed, from the lab to the clinic, in Australia. Clarity is also the first company globally to receive Breakthrough Therapy designation for a PSMA PET imaging agent. Furthermore, of the more than 1,300 applications the US FDA has received for Breakthrough Therapy designation across all therapeutic areas, fewer than half have been awarded[12], and we believe that only a single-digit number of diagnostics have received this designation. This is an incredible accomplishment, and we are proud to see this phenomenal Australian science story unfold.

"The Breakthrough Therapy and Fast Track designations awarded to 64Cu-SAR-bisPSMA further underscore the unmet need and help expedite the development of our optimised product in BCR of prostate cancer, with the goal of bringing it to patients who need it most, as fast as possible. With a next-generation product, we believe we are well positioned to address this growing market opportunity, predicted to exceed US$3Bn by 2029, while better serving patients and their clinicians in the pursuit of our ultimate goal to improve treatment outcomes for people with cancer."

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

(Press release, Clarity Pharmaceuticals, NOV 19, 2026, View Source [SID1234675010])

HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

On November 19, 2026 HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM; HKEX:​13) today announces preclinical data for HMPL-A830 presented at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), held on November 18–20, 2026, in Barcelona, Spain. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate ("ATTC") drug candidate comprises a highly selective and potent KRAS small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor ("EGFR") antibody.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. While recent targeted therapies have validated KRAS (the most dominant RAS isoform) as a viable therapeutic target, significant clinical gaps remain, including safety limitations and disease progression driven by acquired resistance, often mediated by upstream receptor tyrosine kinase upregulation. HMPL-A830 is designed to address this unmet need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.

In vitro profiling demonstrated that its pan-KRAS payload exhibits a dual-action mechanism, simultaneously blocking both KRAS "ON" (GTP-RAF1 binding) and "OFF" (GDP-to-GTP exchange) activities. Potent antiproliferative activity was observed across a broad panel of 55 tumor cell lines harboring diverse KRAS alterations, including G12C, G12D, G12V and G13D mutations, as well as wild-type amplification. HMPL-A830 exhibited high binding affinity and rapid internalization into EGFR-positive cells. It also demonstrated a strong bystander killing effect, effectively eliminating neighboring EGFR-negative tumor cells, while maintaining robust antibody-dependent cellular cytotoxicity (ADCC) activity.

In mouse models, HMPL-A830 showed dose-dependent and robust antitumor efficacy across various EGFR-positive tumor models harboring KRAS alterations. HMPL-A830 achieved more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparative regimens, including its unconjugated antibody, a pan-RAS inhibitor (administered alone or in combination with cetuximab), and a TROP2-targeted Topo I-inhibitor antibody-drug conjugate. Pharmacokinetic and pharmacodynamic (PK/PD) analyses confirmed a stronger and more sustained inhibition of EGFR/KRAS downstream signaling than the naked antibody, alongside a stable drug-to-antibody ratio (DAR) maintained in mouse, monkey, and human plasma.

In September 2026, HUTCHMED Limited (a subsidiary of the Company) entered into an exclusive development and license agreement with a subsidiary of GSK plc ("GSK"), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HUTCHMED Limited is responsible for the global Phase I development program of HMPL-A830. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.

The Phase Ia part of an ongoing global Phase I trial is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).

About HUTCHMED ATTCs

HUTCHMED’s ATTCs represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety.

Built on over 20 years of targeted therapy expertise, the ATTC platforms enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically-delivered small molecule inhibitors, which in turn could ensure safer long-term use and support combinations with chemotherapy and immunotherapy in earlier-line treatments.

About KRAS

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer ("CRC"), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma ("PDAC") patients.1 KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation, and survival.

While recent targeted therapies have validated KRAS as a viable therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard-of-care.

About EGFR

EGFR is a widely expressed receptor tyrosine kinase and established driver of tumor cell proliferation, survival, and disease progression across multiple solid tumors, including CRC, PDAC, and non-small cell lung cancer ("NSCLC"). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS. EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in CRC, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. Together, these provide a strong rationale for the dual targeting of EGFR and KRAS, not only in CRC but also additional indications such as PDAC and NSCLC.

(Press release, Hutchison China MediTech, NOV 19, 2026, View Source [SID1234674994])

Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026

On November 19, 2026 Summit Therapeutics Inc. (Nasdaq: SMMT) reported it will host a corporate update and operational progress conference call and webcast on Monday, November 30, 2026. The call is scheduled to take place at 8:00 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call and webcast details, including dial-in information and webcast link, will be posted on the Investor Relations section of Summit’s website, www.smmttx.com. The archived webcast will be available through the company’s website after the call has concluded.

(Press release, Summit Therapeutics, NOV 19, 2026, View Source [SID1234675012])